Acticor Biotech SAS (ALACT.PA)
| Previous close | 2.7300 |
| Open | 2.8800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.8000 - 2.9500 |
| 52-week range | 2.7200 - 11.0000 |
| Volume | |
| Avg. volume | 2,978 |
| Market cap | 48.509M |
| Beta (5Y monthly) | -0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6700 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- GlobeNewswire
Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke
Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the United-States, Europe, Israel and United Kingdom Confirmation of clinical results communication for the second quarter 2024 Paris, France, November 07, 2023 - 08h00 CET - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the t
Business WireACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of October 31, 2023
PARIS, November 06, 2023--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of October 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).
Business WireActicor Biotech Publishes Its Half-Year Results for 2023 and Provides an Update on Its Clinical Progress
PARIS, October 26, 2023--Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today publishes its half-year results to June 30, 2023, approved by the Board of Directors on October 26, 2023, and provides an update on its latest progress.
